Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2023 | PARP inhibitors for metastatic hormone sensitive prostate cancer

Bertrand Tombal • 17 Mar 2023
EAU 2023
Genitourinary Cancer Prostate Cancer Abiraterone Apalutamide Enzalutamide Niraparib Olaparib Rucaparib Telezaparib

Bertrand Tombal, MD, PhD, Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium, discusses the treatment with PARP inhibitors for metastatic hormone sensitive prostate cancer (mHSPC), including olaparib, rucaparib, niraparib and telezaparib, specifically for those who have progressed on abiraterone, enzalutamide or apalutamide, highlighting the importance for DNA damage response (DDR) testing for these patients. This interview took place at the EAU congress in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bertrand Tombal

1:24
PSA limitations in prostate cancer: advancing treatment de-escalation with imaging biomarkers
Bertrand Tombal • 5 Dec 2023
2:54
Time for treatment de-escalation for mHSPC?
Bertrand Tombal • 5 Jan 2024
2:43
Optimizing PSA recurrence treatment
Bertrand Tombal • 5 Dec 2023
2:10
PSA rise factors & significance of doubling time
Bertrand Tombal • 5 Dec 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals